January 5, 2012. At the FDA Advisory Panel meetings in 2003 and 2005, FDA provided and presented data from the Breast Implant Core studies regarding connective tissue disorder (CTD) signs and symptoms (S/S) and Quality of Life measures.
Read More »On Medical Treatments & Products
Statement of Dr. Diana Zuckerman, Yasmin, Yaz and Other Drospirenone Birth Control Products
December 8, 2011. Dr. Diana Zuckerman spoke at the FDA meeting on the safety of Bayer’s birth control pills Yasmin and Yaz and other drospirenone birth control products, advocating for these high risk drugs to be taken off the market.
Read More »NCHR Testimony at the Senate Aging Committee Hearing on Atypical Antipsychotic Drugs
November 30, 2011. Dr. Diana Zuckerman, the president of NRC, provided a statement for the Senate Aging Committees regarding problems with antipsychotic drugs.
Read More »NCHR Testimony at the FDA Advisory Committee Meeting on Breast Implants
October 24, 2011. Dana Casciotti, NCHR Public Health Research Director, testifies at an FDA advisory meeting on breast implants.
Read More »NCHR Testimony at FDA Advisory Meeting on Breast Implants
September 24, 2011. NRC President, Dr. Diana Zuckerman testifies at an FDA advisory hearing on breast implants.
Read More »